Blog

SC pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial – ESMO

European Society for Medical Oncology/LinkedIn

Mar 27, 2025, 14:45

SC pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial – ESMO

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“As presented at ELCC25, subcutaneous (SC) pembrolizumab – consisting of pembrolizumab co-formulated with berahyaluronidase alfa – demonstrated noninferiority in pharmacokinetics compared with intravenous (IV) pembrolizumab in the phase III MK-3475A-D77 trial. Similar efficacy outcomes were observed.

Patients may prefer SC immunotherapy administration and other potential benefits include reductions in pharmacy preparation, nursing administration time, infusion-chair occupancy and infusion-related adverse events than with IV administration.

Results plus commentary in the ESMO Daily Reporter.”

berahyaluronidase alfa cancer ELCC25 ESMO ESMODailyReporter European Society for Medical Oncology fight against cancer Global fight against cancer IV MK-3475A-D77 trial OncoDaily Oncology pembrolizumab Subcutaneous pembrolizumab

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts

King Charles III Hospitalized Following Side Effects from Cancer Treatment

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris